Results 11 to 20 of about 6,944 (246)

The Proteomic Analysis of Intermittent Fasting Alone or with GLP-1RA in NAFLD Rats [PDF]

Diabetes Metab Syndr Obes
Yimin Shao, Shengya Xu, Yuanyuan Ma, Junqing Zhang, Xiaohui Guo, Tingting Zhang, G H Yuan   +6 more
openalex   +3 more sources

The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study [PDF]

Diabetes & Metabolism Journal, 2023
We compared the glycemic efficacy of treatment intensification between quadruple oral antidiabetic drug therapy and once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA)-based triple therapy in patients with poorly controlled type 2 diabetes ...
Minyoung Kim, Hosu Kim, Kyong Young Kim, Soo Kyoung Kim, Junghwa Jung, Jong Ryeal Hahm, Jaehoon Jung, Jong Ha Baek   +7 more
doaj   +1 more source

Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study [PDF]

Sci Rep
Huasu Zeng, Jingchao Hu, Zhuo Yang, Min Wang, Lin Gao, Zhengde Tang, Junfeng Zhang, Ping Yin, Jun Gu, Changqian Wang   +9 more
openalex   +2 more sources

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies

Metabolites, 2022
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits.
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino   +6 more
doaj   +1 more source

Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany. [PDF]

PLoS ONE, 2016
AIMS:To investigate real-world clinical and patient-related variables associated with initiating GLP-1 receptor agonist (GLP-1RA) treatment relative to initiation of other glucose-lowering therapies in type 2 diabetes (T2D) patients of primary care in ...
Qing Qiao, Susan Grandy, Josh Hiller, Karel Kostev   +3 more
doaj   +1 more source

GLP‐1RA comparative effectiveness against dementia onset relative to other antidiabetic medications in a large, multi‐site cohort of patients with type 2 diabetes [PDF]

Alzheimers Dement
Nerissa Nance, Paola Gilsanz, Andrew J. Karter, Holly Finertie, Julie A. Schmittdiel, Jaejin An, Alyce S. Adams, Caryn Oshiro, Andrea E. Cassidy‐Bushrow, Sarah Krahe‐Dombrowski, Maher Yassin, Sharon Lin, Keanu Izadian, Patrick J. O’Connor, Romain Neugebauer   +14 more
openalex   +2 more sources

Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment

Therapeutic Advances in Endocrinology and Metabolism, 2023
Background: Patients with type 1 diabetes mellitus (T1DM) may have suboptimal glucose control and are interested in the use of adjuvant therapies. Objectives: To determine, from the patients’ perspective, the reasons for initiation of glucagon-like ...
Khary Edwards, Aleksandra Uruska, Anna Duda-Sobczak, Dorota Zozulinska-Ziolkiewicz, Ildiko Lingvay   +4 more
doaj   +1 more source

Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data

Frontiers in Endocrinology, 2022
Clinical studies after marketing have shown that the use of glucagon-like peptide-1 receptor agonist(GLP-1RA) may lead to acute kidney injury(AKI). However, few epidemiological studies have investigated the risk, clinical features, and outcomes of AKI ...
Shichao Dong, Chuan Sun
doaj   +1 more source

A Remotely Delivered GLP-1RA–Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation [PDF]

JMIR Form Res
Rebecca Richards, Michael Whitman, Gina Wren, P.J. Campion   +3 more
openalex   +2 more sources

Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis

European Psychiatry, 2023
Background Recent reports of individuals experiencing suicidal and/or self-injurious behaviors while using liraglutide and semaglutide have heightened the concerns regarding neuropsychiatric safety of Glucagon-like peptide-1 agonists (GLP-1RAs).
Congqin Chen, Rijing Zhou, Fang Fu, Jie Xiao   +3 more
doaj   +1 more source